Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

28.90
-1.0500-3.51%
Post-market: 28.900.00000.00%17:57 EDT
Volume:909.35K
Turnover:26.36M
Market Cap:1.66B
PE:-12.79
High:30.46
Open:29.62
Low:28.37
Close:29.95
52wk High:40.37
52wk Low:4.30
Shares:57.37M
Float Shares:48.42M
Volume Ratio:0.46
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2601
EPS(LYR):-2.2601
ROE:-46.56%
ROA:-25.68%
PB:5.42
PE(LYR):-12.79

Loading ...

Capricor Therapeutics Is Maintained at Buy by Roth Capital

Dow Jones
·
Nov 13, 2025

B. Riley Securities Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
Nov 12, 2025

Capricor Therapeutics price target raised to $13 from $12 at Roth Capital

TIPRANKS
·
Nov 12, 2025

Capricor Therapeutics Q3 net loss widens

Reuters
·
Nov 11, 2025

Capricor Therapeutics Q3 EPS $(0.54) Beats $(0.55) Estimate

Benzinga
·
Nov 11, 2025

Capricor Therapeutics reports third quarter revenue of $0

Reuters
·
Nov 11, 2025

BRIEF-Capricor Therapeutics Q3 EPS USD -0.54

Reuters
·
Nov 11, 2025

Capricor Therapeutics options imply 40.9% move in share price post-earnings

TIPRANKS
·
Nov 11, 2025

Top Stocks With Earnings This Week: Plug, Oklo, Circle And More

Benzinga
·
Nov 10, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 10, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 07, 2025

Capricor Therapeutics announces publication in Biomedicines on Deramiocel

TIPRANKS
·
Nov 03, 2025

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

GlobeNewswire
·
Oct 31, 2025

Capricor Therapeutics Inc. Releases Investor Presentation Highlighting Progress in Duchenne Muscular Dystrophy Program and Exosome Platform Development

Reuters
·
Oct 13, 2025

Capricor Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Oct 08, 2025

Capricor Therapeutics’ Deramiocel Progress and FDA Clarity Underpin Buy Rating

TIPRANKS
·
Sep 27, 2025

Capricor Therapeutics Price Target Maintained With a $24.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 25, 2025

Optimistic Buy Rating for Capricor Therapeutics Driven by Regulatory Progress and Strategic Positioning

TIPRANKS
·
Sep 25, 2025

Capricor Therapeutics Shares Rise After Positive Type A Meeting With FDA

Dow Jones
·
Sep 25, 2025

Capricor approval on track for mid-2026, says JonesResearch

TIPRANKS
·
Sep 25, 2025